JP2017502989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502989A5 JP2017502989A5 JP2016546785A JP2016546785A JP2017502989A5 JP 2017502989 A5 JP2017502989 A5 JP 2017502989A5 JP 2016546785 A JP2016546785 A JP 2016546785A JP 2016546785 A JP2016546785 A JP 2016546785A JP 2017502989 A5 JP2017502989 A5 JP 2017502989A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- combination
- combination medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 15
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 14
- 102400000932 Gonadoliberin-1 Human genes 0.000 claims description 12
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 12
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 12
- 229960001442 gonadorelin Drugs 0.000 claims description 12
- 239000000328 estrogen antagonist Substances 0.000 claims description 10
- 108010069236 Goserelin Proteins 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 229960001603 tamoxifen Drugs 0.000 claims description 7
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 6
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 claims description 5
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims description 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 4
- 229960003690 goserelin acetate Drugs 0.000 claims description 4
- 210000000244 kidney pelvis Anatomy 0.000 claims description 4
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical group C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims description 4
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
- 229960002913 goserelin Drugs 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 108010037003 Buserelin Proteins 0.000 claims description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 229960002184 abarelix Drugs 0.000 claims description 2
- 108010023617 abarelix Proteins 0.000 claims description 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical group C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 2
- 229960002719 buserelin Drugs 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 229960002258 fulvestrant Drugs 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 229960004622 raloxifene Drugs 0.000 claims description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002119 raloxifene hydrochloride Drugs 0.000 claims description 2
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- XYDVHKCVOMGRSY-UHFFFAOYSA-N 4-(4-benzylphenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC(CC=3C=CC=CC=3)=CC=2)=C1 XYDVHKCVOMGRSY-UHFFFAOYSA-N 0.000 description 1
- 101001050286 Homo sapiens Jupiter microtubule associated homolog 1 Proteins 0.000 description 1
- 101000928034 Homo sapiens Proteasomal ubiquitin receptor ADRM1 Proteins 0.000 description 1
- 102100023133 Jupiter microtubule associated homolog 1 Human genes 0.000 description 1
- 102100036915 Proteasomal ubiquitin receptor ADRM1 Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305057 | 2014-01-15 | ||
| EP14305057.3 | 2014-01-15 | ||
| PCT/IB2015/050260 WO2015107461A1 (en) | 2014-01-15 | 2015-01-13 | Pharmaceutical combinations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019167076A Division JP2020023497A (ja) | 2014-01-15 | 2019-09-13 | 組合せ医薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502989A JP2017502989A (ja) | 2017-01-26 |
| JP2017502989A5 true JP2017502989A5 (enExample) | 2018-02-22 |
Family
ID=50033443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546785A Withdrawn JP2017502989A (ja) | 2014-01-15 | 2015-01-13 | 組合せ医薬 |
| JP2019167076A Pending JP2020023497A (ja) | 2014-01-15 | 2019-09-13 | 組合せ医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019167076A Pending JP2020023497A (ja) | 2014-01-15 | 2019-09-13 | 組合せ医薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160331755A1 (enExample) |
| EP (1) | EP3094340A1 (enExample) |
| JP (2) | JP2017502989A (enExample) |
| KR (1) | KR20160101027A (enExample) |
| CN (2) | CN112535688A (enExample) |
| AU (2) | AU2015207723A1 (enExample) |
| BR (1) | BR112016012141A2 (enExample) |
| CA (1) | CA2936783A1 (enExample) |
| MX (1) | MX2016009226A (enExample) |
| RU (2) | RU2020121929A (enExample) |
| WO (1) | WO2015107461A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111757734A (zh) * | 2017-12-28 | 2020-10-09 | 星座制药公司 | 通过组合疗法的ezh2抑制剂的药代动力学增强 |
| WO2023150267A1 (en) * | 2022-02-03 | 2023-08-10 | Maison Amori Oqvpo Llc | Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| US20080161355A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CN101019828A (zh) * | 2007-03-23 | 2007-08-22 | 济南帅华医药科技有限公司 | 一种含磷酸肌醇3－激酶抑制剂及激素类药物的抗癌组合物 |
| PE20090215A1 (es) * | 2007-05-09 | 2009-03-30 | Novartis Ag | Compuestos derivados de imidazopiridazinas como inhibidores de cinasa |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| WO2011130342A1 (en) * | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| PT2592933T (pt) * | 2010-07-16 | 2017-05-23 | Gaweco Anderson | Inibidores de mif e suas utilizações |
| WO2013066483A1 (en) * | 2011-08-31 | 2013-05-10 | Novartis Ag | Synergistic combinations of pi3k- and mek-inhibitors |
| US20150023954A1 (en) * | 2012-03-23 | 2015-01-22 | Memorial Sloan-Kettering Cancer Center | Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition |
| US20150148345A1 (en) * | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
-
2015
- 2015-01-13 RU RU2020121929A patent/RU2020121929A/ru unknown
- 2015-01-13 CN CN202011428621.1A patent/CN112535688A/zh active Pending
- 2015-01-13 EP EP15701257.6A patent/EP3094340A1/en not_active Withdrawn
- 2015-01-13 CN CN201580004798.XA patent/CN105916515A/zh active Pending
- 2015-01-13 CA CA2936783A patent/CA2936783A1/en not_active Abandoned
- 2015-01-13 WO PCT/IB2015/050260 patent/WO2015107461A1/en not_active Ceased
- 2015-01-13 RU RU2016133285A patent/RU2016133285A/ru unknown
- 2015-01-13 JP JP2016546785A patent/JP2017502989A/ja not_active Withdrawn
- 2015-01-13 BR BR112016012141A patent/BR112016012141A2/pt not_active Application Discontinuation
- 2015-01-13 KR KR1020167018718A patent/KR20160101027A/ko not_active Abandoned
- 2015-01-13 US US15/109,704 patent/US20160331755A1/en not_active Abandoned
- 2015-01-13 AU AU2015207723A patent/AU2015207723A1/en not_active Abandoned
- 2015-01-13 MX MX2016009226A patent/MX2016009226A/es unknown
-
2017
- 2017-07-11 US US15/646,494 patent/US10085996B2/en not_active Expired - Fee Related
- 2017-10-10 AU AU2017245302A patent/AU2017245302B2/en not_active Ceased
-
2019
- 2019-09-13 JP JP2019167076A patent/JP2020023497A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2717911T3 (es) | Combinaciones farmacéuticas que comprenden un inhibidor de B-Raf, un inhibidor de EGFR y opcionalmente un inhibidor de PI3K-alfa | |
| CN115279376A (zh) | 用于治疗异常细胞生长的组合疗法 | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| JP2019510832A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2018508516A5 (enExample) | ||
| JP2017530983A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| JP2015038135A5 (enExample) | ||
| MX2015015589A (es) | Composiciones y metodos para el suministro de agentes activos hidrófobos. | |
| MX2015017629A (es) | Combinaciones farmaceuticas. | |
| JP2014525454A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2015510916A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| JP2021502415A (ja) | 癌の処置のためのアパチニブを用いる併用療法 | |
| JP2014523398A5 (enExample) | ||
| JP2018519324A5 (enExample) | ||
| JP2014532648A5 (enExample) | ||
| JP2020529995A5 (enExample) | ||
| MX2015017058A (es) | Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos. | |
| JP2021505669A5 (enExample) |